Cyclin-Dependent Kinase Inhibitor p27Kip1 Controls Growth and Cell Cycle Progression in Human Uterine Leiomyoma
- Author(s)
- Sabarish Ramachandran; Kun-Young Kwon; So-Jin Shin; Sang-Hoon Kwon; Soon-Do Cha; Insoo Bae; Chi-Heum Cho
- Keimyung Author(s)
- Kwon, Kun Young; Shin, So Jin; Kwon, Sang Hoon; Cha, Soon Do; Cho, Chi Heum
- Department
- Dept. of Pathology (병리학)
Dept. of Obstetrics & Gynecology (산부인과학)
- Journal Title
- Journal of Korean Medical Science
- Issued Date
- 2008
- Volume
- 23
- Issue
- 4
- Keyword
- Uterus; Leiomyoma; Cyclin-Dependent Kinase Inhibitor p27; Apoptosis
- Abstract
- The molecular mechanism of the cell-cycle machinery in uterine leiomyoma has not yet been fully elucidated. Among the various types of cell-cycle regulators, p27Kip1 (p27) is considered to be a potent tumor suppressor. To provide further molecular basis for understanding the progression of uterine leiomyoma, our objective was to evaluate the expression level of p27 in normal myometrium and uterine leiomyoma tissue and its effect on cytogenic growth. Western blot analysis, real-time polymerase chain reaction (PCR) and immunohistochemical staining revealed that p27 protein and messenger RNA were down-regulated in uterine leiomyoma tissue and cultured cells compared to normal myometerium. Full-length human p27 cDNA was transferred using a replication-deficient recombinant adenoviral vector (Ad.p27) into uterine leiomyoma cells and evaluated the effect on cell proliferation. Transfection of Ad.p27 into uterine leiomyoma cells resulted in the induction of apoptosis, reduction in viability and proliferation of uterine leiomyoma cells. Our results suggest a new paradigm that down-regulated p27 protein expression is the possible underlying mechanism for the growth of uterine leiomyoma and over-expression of p27 induces cell death. This study provides better understanding of the control exerted by p27 in regulating growth and disease progression of uterine leiomyoma.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.